Clinical trial
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients…
NCT00249002 · Celgene, Industry · Terminated
Key facts
| NCT number | NCT00249002 |
|---|---|
| Title | Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis |
| Official title | A Pilot Phase II Trial Of ABI-007 (A Cremophor El-Free, Protein Stabilized, Nanoparticle Paclitaxel) For The Prevention Of Vascular Access Graft Failure In Patients Undergoing Hemodialysis |
| Lead sponsor | Celgene, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hemodialysis Graft Dysfunction |
| Intervention type | Drug |
| Interventions | ABI-007 |
| Enrollment | 9 |
| Start date | Nov 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Nov 7, 2005 |
| Last update posted | Nov 25, 2019 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: